Cingulate

Cingulate
Cingulate
CING
NASDAQ
3.63 USD
-4.97%

About

Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD).

The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form..

Financials Amount (in millions)

Income statement
Balance sheet
Cash flow

Ratios

Price and Volume
Volume
Ten Day Average Volume 3.3M
Three Month Average Volume 80.9M
High Low
Fifty-Two Week High 187.2 USD
Fifty-Two Week Low 1.8001 USD
Fifty-Two Week High Date 20 Sep 2023
Fifty-Two Week Low Date 14 Aug 2024
Price and Volume
Current Price 7.89 USD
Beta -100,000
Relative Price Change
Four Week Relative Price Change 99.99%
Thirteen Week Relative Price Change -12.36%
Twenty-Six Week Relative Price Change -55.37%
Fifty-Two Week Relative Price Change -95.91%
Year-to-Date Relative Price Change -92.74%
Price Change
One Day Price Change 22.71%
Thirteen Week Price Change -6.21%
Twenty-Six Week Price Change -50.93%
Five Day Price Change -18.58%
Fifty-Two Week Price Change -94.88%
Year-to-Date Price Change -91.41%
Month-to-Date Price Change 86.21%
Per Share Data
Book Value
Book Value Per Share (Last Fiscal Year) -70.60777 USD
Book Value Per Share (Most Recent Quarter) 3.9497 USD
Tangible Book Value Per Share (Last Fiscal Year) -70.60777 USD
Tangible Book Value Per Share (Most Recent Quarter) 3.9497 USD
EBITD
EBITD Per Share (Trailing Twelve Months) -59.9603 USD
Revenue
Revenue Per Share (Last Fiscal Year) 0 USD
Revenue Per Share (Trailing Twelve Months) 0 USD
Dividend
Dividend Per Share (Last Fiscal Year) -99999.99 USD
Dividend Per Share (Trailing Twelve Months) 0 USD
Dividend Per Share (5 Year) -99999.99 USD
Earnings Per Share
Excluding Extraordinary Items (Last Fiscal Year) -312.0005 USD
Excluding Extraordinary Items (Trailing Twelve Months) -141.6024 USD
Normalized (Last Fiscal Year) -312.0005 USD
Basic Excluding Extraordinary Items (Last Fiscal Year) -312.0005 USD
Basic Excluding Extraordinary Items (Trailing Twelve Months) -141.6024 USD
Including Extraordinary Items (Last Fiscal Year) -312.0005 USD
Including Extraordinary Items (Trailing Twelve Months) -141.6024 USD
Cash
Cash Per Share (Last Fiscal Year) 0.5388 USD
Cash Per Share (Most Recent Quarter) 0.4879 USD
Cash Flow Per Share (Last Fiscal Year) -304.1368 USD
Cash Flow Per Share (Trailing Twelve Months) -61.27165 USD
Free Cash Flow Per Share (Trailing Twelve Months) -58.75414 USD
Margins
Cash Flow Revenue
Cash Flow Revenue (5 Year) -100,000
Cash Flow Revenue (Trailing Twelve Months) -100,000
Pretax Margin
Pretax Margin (Trailing Twelve Months) -99,999.99%
Pretax Margin (Last Fiscal Year) -99,999.99%
Pretax Margin (5 Year) -99,999.99%
Gross Margin
Gross Margin (Last Fiscal Year) -99,999.99%
Gross Margin (Trailing Twelve Months) -99,999.99%
Gross Margin (5 Year) -99,999.99%
Operating Margin
Operating Margin (Last Fiscal Year) -99,999.99%
Operating Margin (Trailing Twelve Months) -99,999.99%
Operating Margin (5 Year) -99,999.99%
Net Profit Margin
Net Profit Margin (Last Fiscal Year) -99,999.99%
Net Profit Margin (Trailing Twelve Months) -99,999.99%
Net Profit Margin (5 Year) -99,999.99%
Growth
Book Value
Book Value Per Share (5 Year) -99,999.99%
Tangible Book Value (5 Year) -99,999.99%
Free Operating Cash Flow
Free Operating Cash Flow (5 Year) -99,999.99%
Revenue
Revenue Change MRQ vs 1 Year Ago -99,999.99%
Revenue Growth (3 Year) -99,999.99%
Revenue Change (Trailing Twelve Months) -99,999.99%
Revenue Per Share Growth -99,999.99%
Revenue Growth (5 Year) -99,999.99%
Capital Spending Debt
Capital Spending (5 Year) -99,999.99%
Total Debt (5 Year) -99,999.99%
Dividends
Dividend Growth (3 Year) -99,999.99%
Earnings Per Share
EPS Change MRQ vs 1 Year Ago 95.97%
EPS Change (Trailing Twelve Months) 64.95%
EPS Growth (3 Year) -99,999.99%
EPS Growth (5 Year) -99,999.99%
EBITDA
EBITDA (5 Year) -99,999.99%
EBITDA (5 Year Interim) -99,999.99%
Net Profit Margin
Net Profit Margin Growth (5 Year) -99,999.99%
Valuation
Total Price to Book
Price to Tangible Book (Last Fiscal Year) -100,000
Price to Tangible Book (Most Recent Quarter) 2
Price to Free Cash Flow
Price to Free Cash Per Share (Last Fiscal Year) -100,000
Price to Free Cash Per Share (Trailing Twelve Months) -100,000
Net Debt
Net Debt (Most Recent Quarter) -367,830
Net Debt (Last Fiscal Year) 3.0M
Price to Sales
Price to Sales (Last Fiscal Year) -100,000
Price to Sales (Trailing Twelve Months) -100,000
Price to Earnings
PE Excluding Extraordinary Items (Last Fiscal Year) -100,000
PE Normalized (Last Fiscal Year) -100,000
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) -100,000
PE Excluding Extraordinary Items High (Trailing Twelve Months) -100,000
PE Excluding Extraordinary Items Low (Trailing Twelve Months) -100,000
PE Including Extraordinary Items (Trailing Twelve Months) -100,000
Dividends
Dividend Yield (5 Year) -99,999.99%
Dividend Yield -99,999.99%
Current Dividend Yield 0.00%
Price to Book
Price to Book (Last Fiscal Year) -100,000
Price to Book (Most Recent Quarter) 2
Financial Strength
Debt to Equity
Long Term Debt to Equity (Last Fiscal Year) -100,000
Long Term Debt to Equity (Most Recent Quarter) 0
Payout Ratio
Payout Ratio (Last Fiscal Year) -99,999.99%
Payout Ratio (Trailing Twelve Months) -99,999.99%
Quick Ratio
Quick Ratio (Last Fiscal Year) -100,000
Quick Ratio (Most Recent Quarter) -100,000
Enterprise Value
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) -100,000
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) -100,000
Current Ratio
Current Ratio (Last Fiscal Year) 0
Current Ratio (Most Recent Quarter) 1
Free Cash Flow
Free Cash Flow (Last Fiscal Year) -15,258,640
Free Cash Flow (Trailing Twelve Months) -17,683,820
Net Interest Coverage
Net Interest Coverage (Last Fiscal Year) -29
Net Interest Coverage (Trailing Twelve Months) -47
Total Debt to Equity
Total Debt to Equity (Last Fiscal Year) -100,000
Total Debt to Equity (Most Recent Quarter) 0
Management Effectiveness
Return on Assets
Return on Assets (Last Fiscal Year) -315.98%
Return on Assets (Trailing Twelve Months) -368.85%
Return on Assets (5 Year) -99,999.99%
Return on Equity
Return on Equity (Last Fiscal Year) -99,999.99%
Return on Equity (Trailing Twelve Months) -99,999.99%
Return on Equity (5 Year) -99,999.99%
Return on Investment
Return on Investment (Last Fiscal Year) -99,999.99%
Return on Investment (Trailing Twelve Months) -99,999.99%
Return on Investment (5 Year) -99,999.99%

Cookie Settings

We use cookies to deliver and improve our services, analyze site usage, and if you agree, to customize or personalize your experience and market our services to you. You can read our Cookie Policy here.